Selank and Semax for brain fog: what the evidence says

What did @daniellejohnson_np actually say?

The creator recommends Selank and Semax nasal sprays as a go-to for women in perimenopause experiencing "brain fog, low motivation" and that feeling of knowing you're capable but your brain "just is not cooperating." She says these peptides help with "focus, mental clarity, productivity" without causing overstimulation or anxiety, and that users notice effects "within the first 30 to 60 minutes." She invites followers to DM her with questions.

To be fair, she keeps the claims relatively contained. She doesn't say these peptides cure anything, and she doesn't throw out specific dosing numbers on camera. But framing two research-stage compounds as staples for "busy women" without once mentioning that neither is FDA-approved, that human trial data is extremely thin, or that perimenopausal brain fog has established clinical pathways, is a meaningful gap. That omission matters when you have 6,800 people watching.

Does the science back this up?

Partially, and only in a narrow, heavily caveated way. Most Selank and Semax research comes from Russian institutions, which creates real problems for independent replication and peer review standards.

Semax is a synthetic analog of a fragment of ACTH (adrenocorticotropic hormone). Animal studies and a limited number of small Russian clinical trials suggest it may increase BDNF (brain-derived neurotrophic factor) and have neuroprotective effects. One study by Shadrina et al. (2010, Journal of Molecular Neuroscience) showed upregulation of genes related to serotonin and dopamine pathways in rats. Human data is sparse and largely unpublished in Western peer-reviewed journals.

Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide. It has been studied primarily for anxiolytic effects in Russia, with Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) reporting reduced anxiety in patients with generalized anxiety disorder in a small trial. The mechanism appears to involve GABA-A receptor modulation, which is pharmacologically plausible. But again, large randomized controlled trials do not exist in Western literature.

The 30 to 60 minute onset claim is plausible for intranasal delivery, which bypasses first-pass metabolism. That part is not unreasonable.

What did they get wrong (or right)?

What she got right: the pharmacology of intranasal delivery is legitimate, the anxiety-without-overstimulation profile is consistent with what limited data exists on Selank's GABAergic activity, and she does not make absurd disease-cure claims.

What she got wrong, or at minimum incomplete:

• Framing these as solutions for perimenopausal brain fog without acknowledging that perimenopause-related cognitive symptoms are primarily driven by estrogen fluctuation. There is actual clinical evidence for hormone therapy, not for Selank or Semax, in this context.
• The "staple" framing implies a level of established safety and efficacy that simply does not exist. Neither compound has gone through FDA approval. Long-term safety data in humans is essentially nonexistent.
• Inviting 6,800 followers to DM her for personalized peptide guidance is a clinical consult pipeline dressed up as social media engagement. That is a regulatory gray zone at best.
• She never mentions that these are compounded preparations in the US, which means quality, purity, and concentration vary by pharmacy. That is not a minor detail.

What should you actually know?

If you are a woman in perimenopause experiencing brain fog, the first-line conversation should be with a clinician about hormone levels, thyroid function, sleep quality, and yes, potentially hormone therapy if appropriate. Those interventions have randomized trial data behind them.

Selank and Semax are not snake oil. The mechanistic rationale is real and the early research is genuinely interesting. But interesting early research is not the same as proven efficacy in humans, and it is especially not the same as proven efficacy in perimenopausal women specifically, because that population has never been studied in this context.

In the US, both compounds are available only through compounding pharmacies, which means they are not FDA-approved and are not subject to the same manufacturing oversight as approved drugs. Quality varies. Sourcing matters enormously. If you are considering either compound, that conversation belongs in a clinical setting with someone reviewing your full history, not in a DM thread.

One more thing worth saying plainly: a fast onset does not mean a safe or effective compound. Plenty of substances work fast. That is not a proxy for clinical validation.